[HTML][HTML] Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
Background Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation
antigen (BCMA) on multiple myeloma (MM) produces fast but not long-lasting responses …
antigen (BCMA) on multiple myeloma (MM) produces fast but not long-lasting responses …
[HTML][HTML] Preclinical and nonclinical characterization of HPN217: a tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the …
CL Law, W Aaron, R Austin, M Barath, E Callihan… - Blood, 2018 - Elsevier
About 31,000 new cases of multiple myeloma (MM) will be diagnosed in the US in 2018. In
addition to chemotherapeutic agents, several targeted therapies utilizing distinct …
addition to chemotherapeutic agents, several targeted therapies utilizing distinct …
Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes
We assessed the expression pattern and clinical relevance of BMPs and related molecules
in multiple myeloma (MM). MM bone-marrow samples (n= 32) had increased BMP4, BMP6 …
in multiple myeloma (MM). MM bone-marrow samples (n= 32) had increased BMP4, BMP6 …
PB2082: BONE MORPHOGENIC PROTEIN-6 PROMOTES THE PROLIFERATION AND INHIBITS APOPTOSIS IN MULTIPLE MYELOMA
J Fu, X Cui - HemaSphere, 2023 - journals.lww.com
Background: Previous studies have shown that BMP6 could significantly inhibit the
proliferation of myeloma cell lines and in vitro angiogenesis and is considered a protective …
proliferation of myeloma cell lines and in vitro angiogenesis and is considered a protective …
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
YT Tai, C Acharya, G An, M Moschetta… - Blood, The Journal …, 2016 - ashpublications.org
Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …
[HTML][HTML] Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model
C Weiser, MV Petkova, B Rengstl, C Döring… - Oncotarget, 2018 - ncbi.nlm.nih.gov
The mechanisms involved in malignant transformation of mature B and T lymphocytes are
still poorly understood. In a previous study, we compared gene expression profiles of the …
still poorly understood. In a previous study, we compared gene expression profiles of the …
Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma
MME de Jong, C Fokkema, N Papazian… - Blood, 2022 - ashpublications.org
Background: In many solid cancers, increased numbers of intra-tumoral neutrophils are
associated with poor prognosis. Interestingly, and in contrast to peripheral tissues, the bone …
associated with poor prognosis. Interestingly, and in contrast to peripheral tissues, the bone …
[HTML][HTML] T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma
K Bezverbnaya, V Lau, C Aarts, G Denisova, A Afsahi… - Blood, 2018 - Elsevier
Despite recent therapeutic developments, multiple myeloma remains an incurable plasma
cell malignancy. Poor prognosis for myeloma patients relapsing post-transplant calls for the …
cell malignancy. Poor prognosis for myeloma patients relapsing post-transplant calls for the …
[PDF][PDF] Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers 2021, 13, 216
T Hideshima, KC Anderson - 2021 - go7publish.com
The multiple myeloma (MM) bone marrow (BM) microenvironment consists of different types
of accessory cells. Both soluble factors (ie, cytokines) secreted from these cells and …
of accessory cells. Both soluble factors (ie, cytokines) secreted from these cells and …